Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune diseases. The drugs have the potential to become the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. The company has a lead project in myasthenia gravis as well as a second project in ANCA vasculitis. Toleranzia is listed on the Nasdaq First North Growth Market and backed by strongly committed renowned specialist investors.